Drug intelligence / Profile preview

Colflex Probium

Development stage: Unknown
Lead developer: Mantecorp Saúde
Modality: Peptides, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Colflex Probium is a combination nutraceutical product developed by Mantecorp Saúde (a division of Hypera Pharma) and marketed in Brazil. It is formulated to support joint health and intestinal balance. The product contains non-denatured type II collagen, which is intended to maintain cartilage integrity and modulate the immune response against joint tissues through oral tolerance. Additionally, it includes a probiotic blend consisting of *Lactobacillus acidophilus* NCFM and *Bifidobacterium lactis* HN019, which support gut microbiota health and systemic immune function. It is primarily used as a dietary supplement for individuals with joint wear or osteoarthritis.

Brand names: Colflex Probium
Other names: Colflex Probium

Targets

COL2 (Type II Collagen)

Beyond the preview

Go deeper on Colflex Probium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colflex Probium.

Explore the full profile